Skip to main content
Dr Elaine Dunlop

Dr Elaine Dunlop

Lecturer

School of Medicine

Email
dunlopea@cardiff.ac.uk
Telephone
+44 (0)29 2068 7785
Campuses
Cancer Genetics Building, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN
Users
Available for postgraduate supervision

Overview

'Working towards tailored therapies for inherited diseases and cancer'

My research centres on the inherited conditions, Tuberous Sclerosis Complex (TSC) and Birt-Hogg-Dubé (BHD) syndrome where patients are predisposed to develop cysts and tumours. I aim to understand what is malfunctioning in these cells at a molecular level, with the goal of identifying weaknesses which could be specifically targeted by therapies. As there is crossover between the altered growth pathways observed in these genetic diseases and the pathways which are at fault in sporadic cancer, these future treatments could also be effective for the wider cancer community. Therefore, through a better understanding of disease processes we can work towards stratifying patients based on the genetics of their disease and treating them with appropriately tailored therapies.

Professional Network Sites

  • ResearchGate: https://www.researchgate.net/profile/Elaine_Dunlop
  • Publons: https://publons.com/researcher/1555538/elaine-a-dunlop
  • ORCiD: https://orcid.org/0000-0002-9209-7561

Research Funding

  • Tuberous Sclerosis Association
  • Tuberous Sclerosis Complex Research Program – Department of Defense, Congressionally Directed Medical Research Programs
  • TSC Alliance

Biography

Education and Qualifications

2019 FHEA - Fellow of the Higher Education Academy

2006 PhD (Centre for Cancer Research and Cell Biology) Queen’s University, Belfast

2003 BSc (Hons) Biochemistry, First Class, Queen’s University, Belfast

Awarded Tim Bramley Prize (Top Biochemistry student, 2003) & John Sinclair Porter Scholarship (2001)

Career Overview

  • Jan 2019 – present     Lecturer, Division of Cancer & Genetics/Centre for Medical Education,                                            Cardiff University
  • Jul 2015 – Jan 2019    Research Fellow, Division of Cancer & Genetics, Cardiff University
  • Mar 2013 – Jul 2015   Research Associate, Institute of Cancer & Genetics, Cardiff University
  • Jan 2011 – Feb 2013  Myrovlytis Trust Research Fellow, Institute of Cancer & Genetics, Cardiff                                      University
  • May 2007 – Dec 2010 Research Associate, Institute of Medical Genetics, Cardiff University
  • Oct 2006 – Apr 2007   Special Research Scholar, Haematology Research, Queen’s University,                                      Belfast

Professional memberships

  • 2020 - present    Member of the UK Society for Extracellular Vesicles
  • 2019 - present    Fellow of the Higher Education Academy
  • 2016                   Welsh Crucible Participant
  • 2016 - present    Member of the European Association for Cancer Research
  • 2014                   Associate Fellow of the Higher Education Academy

Committees and reviewing

  • Editorial Board member, PeerJ
  • Editorial Board member, Cancers
  • Reviewer for journals including Autophagy, British Journal of Cancer, Scientific Reports, as well as several MDPI journals.

Publications

2019

2018

2017

2016

2014

2013

2012

2011

2010

2009

2007

2006

Teaching

I am the route lead for the intercalated BSc in Genomic Medicine (commencing September 2021). Interested students are welcome to contact me for more information about the course.

Within the Genomic Medicine course, I am also:

  • Module lead for Fundamentals of Genetics and Genomics
  • Project co-ordinator for Genomic Medicine research projects

I contribute to undergraduate MBBCh C21 curriculum delivery through:

  • Year 1 – Student Selected Component, Literature Review
  • Year 2 – Case Based Learning Facilitator
  • Year 2 - Student Selected Component

I also contribute to Medical Pharmacology and other intercalated BSc Programmes

  • Molecular Genetics and Cell Biology module
  • Critical Analysis and Scientific Methods module
  • Research Supervisor to laboratory based Intercalated Projects

I am a personal tutor for MBBCh and BSc Genomic Medicine students.

I am a Fellow of the Higher Education Academy.

I am a STEM Ambassador, contributing to outreach activities involving school children and patient groups. These include the School of Medicine 'Science in Health Live' event and the Life Sciences Challenge.

Research overview

My research focuses on the signalling pathways underlying genetic diseases and cancer. Much of my work is concentrated on the mammalian target of rapamycin complex 1 (mTORC1) signalling pathway which controls cell growth, and is disrupted in a number of genetic tumour-disposition syndromes, such as tuberous sclerosis complex (TSC) and Birt-Hogg-Dubé (BHD) Syndrome, as well as in sporadic cancer. My research interests are all linked to signalling mechanisms that are drivers of cancer, including processes such as autophagy, mitochondrial biogenesis and metastasis. Recently I have expanded my research to examine the contribution of the microenvironment to genetic disease and am exploring potential predictive biomarkers of disease.

The overall aim of my research is to gain sufficient understanding of the defects underlying TSC and BHD to identify pathways that could be targeted to bring therapeutic benefit to patients. Due to the crossover between the altered signalling pathways seen in TSC, BHD and cancer, the broader scope of my future research is to determine whether these therapies are also effective on stratified sporadic cancers. I work closely with the wider TSC research team at Cardiff, which includes clinicians and geneticists to find cellular mechanisms that can be exploited for potential therapy. I also have strong collaborations with the Cardiff University Tissue Microenvironment Group.

Scientific Contribution

  • Therapeutic targeting of mTORC1-driven cells. My recent work has used knowledge of the points of stress in TSC-deficient cells to identify potential therapeutic targets. We have explored the use of chemical agents and the repositioning of FDA approved drugs in order to preferentially induce cell death in TSC-deficient cells. We discovered that a combination of nelfinavir and bortezomib selectively kills TSC2-deficient cell lines in vitro and reduces tumour volume in vivo, indicating that targeting endoplasmic reticulum stress in combination with proteasomal inhibition could be a viable strategy to treat TS patients. The combination was also effective in sporadic cancer cell lines with mTORC1 hyperactivity, indicating potential broader applications.
  • Exploring mTORC1 cellular signalling mechanisms. My research has better characterized the interactions between the various proteins involved in mTORC1 and we were the first to identify a novel feedback loop allowing the ULK1 kinase involved in autophagy to turn off mTORC1 signalling through specific phosphorylation events. Additionally, two collaborative publications have analysed the role of the TSC proteins at the peroxisome and the influence of arginine on the TSC2-Rheb signalling axis. This work has enhanced our understanding of the mTORC1 signalling network which is known to be dysregulated in many human diseases.
  • Understanding Birt-Hogg-Dubé (BHD) Syndrome. The cellular function of the tumour suppressor protein, folliculin (FLCN), responsible for BHD syndrome is not well characterized. Over the course of my Myrovlytis Trust Fellowship, I revealed altered homeostatic pathways in FLCN-deficient cells, including working with collaborators to show that FLCN plays a role in AMPK signalling, leading to mitochondrial biogenesis, increased ROS production and a conversion towards Warburg metabolic reprogramming. Additionally, I discovered that FLCN is necessary for efficient basal autophagy, interacts with two key components of the autophagy machinery and is a new substrate of ULK1. We also confirmed autophagy defects in tumour samples from BHD patients. This work has helped elucidate the function of FLCN and provide an insight into the homeostatic changes in the cells of BHD patients.

Supervision

Past projects

Co-supervisor for Rachel-Ann Russell  -  Genetic instability upon the loss of the tumour suppressor
folliculin (FLCN) (PhD awarded 2019)

Co-supervisor for Henry McCann - New drug therapies to kill TSC2-deficient cell lines (PhD awarded 2019)

Engagement

Outreach activities

My first involvement in public engagement was through the Beacon Researchers in Schools scheme in 2010, running Genetics workshops at Duffryn High School, Newport. Following this, I became a STEM Ambassador, and have regularly undertaken a range of activities since.

I have contributed to outreach activities organised by others for schoolchildren, such as the School of Medicine ‘Life Sciences Challenge’ and 'Science in Health Live' events. I have also collaborated with teachers to deliver bespoke events, such as a PCR/gel electrophoresis experience and careers talks.

I have participated in events for the general public, including Wales Cancer Research Centre’s ‘How do we develop new cancer drugs?’ event in 2017 and 'Pint of Science' in Cardiff in 2019. I have also spoken about my research to patient groups, such as at the Tuberous Sclerosis Association’s Big Day 2018 and the TSA Welsh Info Day 2019 and 2020.